Search

everythinglearnresearchcommunity

for

Search:↓

SH-MSCs gel reduced IL-6 and increased TGF-β, suggesting it could treat alopecia.

Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.

The conclusion is that emotional support and a variety of treatments are important for alopecia areata, but more research is needed.

The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.

Trichloroacetic acid is a safe and effective treatment for hair loss in alopecia areata patients.

Clinical signs don't match inflammation levels in lichen planopilaris and frontal fibrosing alopecia.

Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.

Alopecia areata is a type of hair loss that can lead to complete baldness, often associated with other autoimmune conditions, and half of the cases may see hair return within a year.

The dog with an Alopecia Areata-like condition showed signs of an autoimmune disease and partially regrew hair without treatment, suggesting dogs could be models for human AA research.

Where a rhesus macaque used to live can affect its chances of getting alopecia later in life, and females are more likely to be affected than males.

The research suggests that autophagy-related genes might play a role in causing alopecia areata.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Cases of alopecia areata and its impact on life quality rose globally, but when adjusted for age, the rates decreased, especially in poorer regions.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Patients with alopecia areata in Saudi Arabia understand the condition's seriousness but still face significant psychological challenges.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

More severe hair loss in alopecia areata greatly impacts patients and caregivers.

New treatments targeting T-cell pathways are needed for better alopecia areata management.

Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Alopecia areata is increasing globally, with disparities needing better prevention and support.

Alopecia areata in Taiwan has a high disease burden and needs better research and diagnostic criteria.

Significant, lasting hair regrowth is needed to improve how patients with Alopecia Areata feel about their condition.

Patients with Alopecia Areata are willing to trade life duration for better quality of life.

The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.

Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.

Baricitinib improves quality of life and reduces anxiety and depression in severe alopecia areata patients with hair regrowth.

Alopecia areata severely impacts quality of life, mental health, and work productivity.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.